IceCure's ProSense® Achieves Remarkable Kidney Cancer Treatment Results Reflecting 90% Recurrence-Free Rate

IceCure's ProSense® and Its Impact on Kidney Cancer Treatment

At the recent European Conference on Interventional Oncology (ECIO) 2026 held in Basel, Switzerland, IceCure Medical Ltd. presented groundbreaking data on its ProSense® device, showcasing a remarkable 89.4% recurrence-free rate in patients with small tumors. This impressive statistic is part of a larger narrative surrounding innovation in cancer treatments, as minimal-invasive methodologies are becoming increasingly popular among both patients and healthcare providers.

Understanding IceCure's ProSense® Technology

ProSense® utilizes cutting-edge cryoablation technology, a method where tumors are destroyed through freezing. This technique offers a less invasive alternative to traditional surgical methods, allowing for shorter recovery times and reduced surgical risks. IceCure's technology is currently focused on treating small tumors, particularly in the kidneys, breasts, lungs, and bones.

With the FDA's clearance for the ProSense® system for early-stage breast cancer, interest in its application for similar conditions is on the rise, evidenced by the overbooked hands-on training courses during the ECIO conference. In fact, the presentations led by respected figures in oncological research highlighted not only the efficacy of ProSense® but also the growing recognition of cryoablation as a standard-of-care treatment option.

Key Findings from the ICESECRET Trial

The ICESECRET trial provided compelling results that further validate the effectiveness of ProSense® in treating kidney cancer. The metrics from this study revealed that among 114 patients, a significant 83.9% remained recurrence-free at a median follow-up period of 4 years, emphasizing the long-term efficacy of cryoablation. Notably, in patients whose tumors were 3 cm or smaller, the recurrence-free rate soared to 89.4%. Such results underscore the potential of ProSense® to be an integral part of the interventional oncology landscape.

The trial also reported minimal impact on renal function and hemoglobin levels, with short average patient hospital stays of just 1.3 days, solidifying the position of cryoablation as a safe treatment approach for patients with small renal masses.

Breast Cryoablation Studies Highlight Excellent Patient Outcomes

The momentum garnered at ECIO was not limited to kidney cancer. Data presented on breast cryoablation showcased outstanding outcomes, with a study from Turkey reporting no residual cancer in patients at 6 and 12 months following the procedure. A remarkable 100% of the participants noted excellent cosmetic results, indicating that cryoablation does not only serve a medical purpose but also addresses aesthetic considerations.

Another independent analysis focused on fibroadenomas in Hungary demonstrated a substantial volume reduction of 92.9% after treatment with ProSense®, with a low mean procedure time of just over 13 minutes. These studies collectively reinforce ProSense®'s versatility across various oncological applications, revealing its ability to address multiple conditions effectively and efficiently.

Future Directions for IceCure Medical

Eyal Shamir, the CEO of IceCure Medical, expressed optimism regarding the future of ProSense®. During the conference, he highlighted the growing global interest in the cryoablation approach and the favorable reception it has received from the medical community. The positive responses from participating physicians in workshops and training sessions illustrate a burgeoning acceptance of cryoablation as a primary treatment option.

The dedicated course on breast cryoablation at ECIO, which attracted an overwhelming number of attendees, exemplifies a clear shift towards recognizing and implementing minimally invasive options in surgical oncology. ProSense® has positioned itself as a leader in this space, supported by solid clinical data and positive feedback from leading oncologists.

As IceCure continues to drive advancements in cryoablation therapy, the potential for blending safety, efficacy, and convenience in treating various cancers appears promising. With ongoing clinical data and increasing acceptance in the medical community, ProSense® is likely to remain at the forefront of innovations in cancer treatment for years to come.